# US 2014/0194512 A1 · Compositions comprising docosapentaenoic acid and methods of use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194512 A1 - Document ID: US20140194512A1 - Status: Published application - Kind: A1 - Application number: 14/207,099 - Filed: 2014-03-12 - Published: 2014-07-10 - Earliest claimed: 2012-06-17 - Assignees: Matinas BioPharma, Inc. - Applicants: Matinas BioPharma, Inc. - Inventors: Abdel Aziz FAWZY; George BOBOTAS; Ihor TERLECKYJ; Roelof RONGEN - Web page: https://patentgrep.com/patent/US20140194512A1 ## CPC - A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557) - A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract Orally administrable composition comprising fatty acids comprising docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA). The compositions can be used for the treatment or prophylaxis of a variety of conditions, including liver-related conditions. ## Claims ### Claim 1 A pharmaceutical composition comprising docosapentaenoic acid (DPA) and docosahexaenoic acid (DHA) in an amount of at least 60% of the total amount of the fatty acids present in the composition, wherein the ratio of DPA to DHA (DPA:DHA) is between about 10:1 to about 1:10. ### Claim 2 (depends on 1) The pharmaceutical composition of claim 1, wherein the composition comprises DPA and DHA in an amount of at least 75% of the total amount of the fatty acids present in the composition. ### Claim 3 (depends on 1) The pharmaceutical composition of claim 1, wherein the composition comprises DPA and DHA in an amount of at least 80% of the total amount of the fatty acids present in the composition. ### Claim 4 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DPA to DHA (DPA:DHA) is between about 5:1 to about 1:5. ### Claim 5 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DPA to DHA (DPA:DHA) is between about 2:1 to about 10:1. ### Claim 6 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DPA to DHA (DPA:DHA) is between about 2:1 to about 8:1. ### Claim 7 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DPA to DHA (DPA:DHA) is between about 2:1 to about 5:1. ### Claim 8 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DPA to DHA (DPA:DHA) is between about 3:1 to about 5:1. ### Claim 9 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DHA to DPA (DHA:DPA) is between about 2:1 to about 10:1. ### Claim 10 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DHA to DPA (DHA:DPA) is between about 2:1 to about 8:1. ### Claim 11 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DHA to DPA (DHA:DPA) is between about 2:1 to about 5:1. ### Claim 12 (depends on 1) The pharmaceutical composition of claim 1, wherein the ratio of DHA to DPA (DHA:DPA) is between about 3:1 to about 5:1. ### Claim 13 (depends on 1) A method of treating, preventing, reducing the occurrence of, and improving symptoms associated with a liver-related disease or condition in a subject in need thereof, comprising administering to the subject a composition of claim 1. ### Claim 14 (depends on 13) The method of claim 13, wherein the liver-related disease or condition is selected from the group consisting of: fatty liver, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), alcoholic steatohepatitis (ASH), hepatitis, HIV (human immunodeficiency virus) infection, drug-induced fatty liver or sequelae, liver failure, liver transplantation, transplanted liver failure, liver damage associated with renal failure or disease, abnormally elevated liver enzymes, or type 2 diabetes. ### Claim 15 (depends on 1) A method of reducing expression of HMG-CoA reductase in a subject in need thereof, comprising administering to the subject a composition of claim 1. ### Claim 16 (depends on 1) A method of reducing levels of HMG-CoA reductase in a subject in need thereof, comprising administering to the subject a composition of claim 1. ### Claim 17 (depends on 1) A method of reducing the expression of proprotein convertase subtilisin/kexin type 9 (PCSK9) in a subject in need thereof, comprising administering to the subject a composition of claim 1. ### Claim 18 (depends on 1) A method of reducing levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) in a subject in need thereof, comprising administering to the subject a composition of claim 1. ### Claim 19 A method of treating, preventing, reducing the occurrence of, and improving symptoms associated with a liver-related disease or condition in a subject in need thereof, comprising administering to the subject a composition comprising docosapentaeoic acid (DPA) and docosahexaenoic acid (DHA) in a daily dosage amount of between 200 mg/day and 8,100 mg/day. ### Claim 20 (depends on 1) The method of claim 1, wherein the composition comprises docosapentaeoic acid (DPA) and docosahexaenoic acid (DHA) in a daily dosage amount of between 300 mg/day and 6,100 mg/day.